The Phase 3 clinical trial (HARMONi‐2 or AK112‐303) was designed to compare the efficacy of AK112 monotherapy against pembrolizumab as a first‐line treatment in cases of locally advanced or metastatic NSCLC with positive PD‐L1 expression (PD‐L1 TPS ≥ 1%). The gene discussed is CD274; the disease is non-small cell lung carcinoma.